Brian H. Johnstone
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$2.6MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $2.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 11, 2026 | NIH | SBIR Phase II Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | $580K | OSSIUM HEALTH INC |
| Sep 2, 2025 | NIH | SBIR Phase II Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | $1.0M | OSSIUM HEALTH INC |
| Aug 14, 2024 | NIH | SBIR Phase II Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | $375K | OSSIUM HEALTH INC |
| Jun 28, 2021 | NIH | SBIR Phase I A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance | $142K | OSSIUM HEALTH INC |
| Aug 18, 2020 | NIH | SBIR Phase I Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | $300K | OSSIUM HEALTH INC |
| Jul 8, 2020 | NIH | SBIR Phase I A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance | $157K | OSSIUM HEALTH INC |
Peer ranks
Federal funding#747
Awards as PI#315
Patents#273
Companies
- OSSIUM HEALTH INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.